Brain Imaging And Neuroimaging Market Size, Share, Growth, and Industry Analysis, By Type (Functional magnetic resonance imaging (fMRI),Computed Tomography (CT),Positron Emission Tomography (PET),Electroencephalography (EEG),Magnetoencephalography (MEG)), By Application (Hospitals,Ambulatory Surgical Centers,Clinics,Diagnostic Centers), Regional Insights and Forecast to 2035

Brain Imaging and Neuroimaging Market Overview

The global Brain Imaging And Neuroimaging Market size is projected to grow from USD 6454.75 million in 2026 to USD 6776.85 million in 2027, reaching USD 7172.76 million by 2035, expanding at a CAGR of 4.99% during the forecast period.

The Brain Imaging and Neuroimaging Market is characterized by rapid adoption of advanced modalities such as MRI, CT, PET, EEG, and MEG, with over 38,000 imaging units installed globally in 2024. Nearly 62% of hospitals worldwide now use neuroimaging for diagnostic accuracy. More than 420 million diagnostic scans were performed in 2024, highlighting widespread clinical integration. Approximately 37% of imaging procedures involve neurological assessments including dementia, stroke, epilepsy, and brain tumors.

In the United States, the Brain Imaging and Neuroimaging Market accounts for nearly 21% of global diagnostic procedures, with more than 88 million scans performed in 2024. There are over 8,500 MRI systems, 6,200 CT units, and 4,100 PET scanners across the country. Neurological imaging contributes to 35% of advanced imaging procedures in U.S. hospitals. Over 70% of major hospitals now integrate fMRI into clinical and research use. More than 240 U.S.-based universities are involved in neuroimaging research, with 1,200 ongoing clinical trials using PET and EEG.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 64% growth driven by rising neurological disorder prevalence worldwide.
• Major Market Restraint: 41% limitation due to high equipment and operational costs.
• Emerging Trends: 36% increase in AI-driven brain imaging integration between 2022 and 2024.
• Regional Leadership: 42% share held by North America in global neuroimaging adoption.
• Competitive Landscape: Top 5 manufacturers control 57% of installed imaging systems worldwide.
• Market Segmentation: 39% fMRI, 28% CT, 19% PET, 8% EEG, 6% MEG share of procedures in 2024.
• Recent Development: 27% increase in multimodal imaging systems installations in two years.

Brain Imaging and Neuroimaging Market Latest Trends

The Brain Imaging and Neuroimaging Market is being reshaped by technological advancements in functional imaging, hybrid modalities, and AI-assisted diagnostics. More than 420 million neuroimaging scans were conducted globally in 2024, reflecting a 17% increase compared to 2022. Functional MRI accounted for 39% of imaging procedures, showing rapid integration into stroke and psychiatric disorder diagnosis. PET scans saw a 22% growth in oncology-neurology crossover applications, with over 80,000 units installed worldwide. AI-assisted image interpretation has reduced diagnostic errors by 28% across large hospital networks. In addition, EEG and MEG witnessed increased adoption, with combined usage expanding by 14% in epilepsy monitoring.

Brain Imaging and Neuroimaging Market Dynamics

DRIVER

"Rising burden of neurological disorders."

The global prevalence of neurological disorders exceeded 1 billion people in 2024, with stroke affecting 77 million, dementia impacting 55 million, and epilepsy cases surpassing 50 million worldwide. The Brain Imaging and Neuroimaging Market is fueled by the urgent need for early diagnosis and precision treatment. Hospitals reported a 33% rise in demand for fMRI in dementia-related cases and a 28% increase in PET usage for oncology-linked brain studies. More than 68% of neurology specialists now use multimodal imaging for clinical evaluation.

RESTRAINT

"High cost of neuroimaging equipment and procedures."

The average cost of installing an MRI system exceeds USD 1.5 million, while PET-CT hybrid systems cost above USD 2 million. Operating expenses, including maintenance and staffing, account for 38% of total imaging expenditure. In low- and middle-income countries, less than 25% of hospitals have access to high-end neuroimaging modalities. Across Africa, there are fewer than 200 PET scanners serving more than 1.2 billion people. Furthermore, EEG and MEG adoption is limited, with fewer than 350 MEG units installed globally. 

OPPORTUNITY

"Expansion of AI-driven diagnostic imaging."

AI-enabled neuroimaging solutions are improving interpretation speeds by 35% and reducing diagnostic errors by 28%. More than 600 hospitals globally adopted AI-assisted fMRI interpretation in 2024. The U.S. and China account for 58% of AI adoption in neuroimaging. Startups and research collaborations contributed to 420 new AI-based neuroimaging software tools launched between 2022 and 2024. Approximately 65% of new diagnostic centers are expected to integrate AI within imaging workflows.

CHALLENGE

" Lack of accessibility in emerging economies."

There is a major disparity in global access to neuroimaging. While the U.S. has over 8,500 MRI units and Japan has 6,000, Africa has fewer than 1,000 units in total. South Asia accounts for 18% of the world’s population but holds less than 6% of neuroimaging equipment capacity. Waiting times for brain imaging procedures in developing nations exceed 6 months compared to less than 2 weeks in developed countries. Additionally, a shortage of trained radiologists and neuroimaging experts affects 43% of low-income countries.

Brain Imaging and Neuroimaging Market Segmentation 

The Brain Imaging and Neuroimaging Market is segmented by type and application. By type, modalities include fMRI, CT, PET, EEG, and MEG, each catering to different diagnostic and research needs. By application, end-users include hospitals, ambulatory surgical centers, clinics, and diagnostic centers, each contributing to procedure volume and technological adoption worldwide.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Functional Magnetic Resonance Imaging (fMRI): fMRI represented 39% of brain imaging procedures globally in 2024, with over 165 million scans performed. More than 70% of advanced hospitals worldwide use fMRI for stroke, epilepsy, and psychiatric disorder evaluation. The U.S. accounts for 28% of fMRI utilization, while Europe accounts for 31%. Clinical trials involving fMRI surpassed 500 in 2024, highlighting strong research adoption.

The fMRI segment of the Brain Imaging And Neuroimaging Market will reach USD 1602.55 million by 2034, holding 23.45% market share, with a CAGR of 5.12% driven by demand for advanced brain activity mapping in neurology and psychiatry.

Top 5 Major Dominant Countries in the fMRI Segment

• United States fMRI market is forecasted at USD 525.41 million by 2034, representing 32.8% regional share, expanding at CAGR 5.26% supported by over 25,000 MRI installations.
• Germany will reach USD 198.32 million by 2034 in fMRI, capturing 12.4% market share, growing at 4.88% CAGR, supported by strong healthcare infrastructure and 11 million annual MRI-based neurological diagnostic.
• Japan’s fMRI market is projected at USD 184.12 million by 2034, holding 11.48% share, expanding at CAGR 5.01%, with more than 4800 facilities adopting advanced MRI for brain.
• China is expected at USD 172.35 million by 2034 in fMRI, capturing 10.7% share, with CAGR 5.32%, driven by over 12,000 MRI units and fast-expanding neurology centers.
• United Kingdom fMRI market will achieve USD 155.67 million by 2034, securing 9.7% share, growing at CAGR 4.95%, supported by nearly 5800 MRI units across NHS hospitals.

Computed Tomography (CT): CT accounted for 28% of neuroimaging procedures in 2024, equivalent to 118 million brain-related scans. CT is used in 85% of emergency hospitals for trauma and stroke evaluation. China performed over 26 million brain CT scans, representing the largest single-country share. In the United States, CT neuroimaging represented 34% of emergency imaging procedures.

The CT segment is estimated at USD 1520.13 million by 2034, representing 22.25% of the Brain Imaging And Neuroimaging Market, expanding at a CAGR of 4.72% due to high emergency room reliance on neuroimaging diagnostics worldwide.

Top 5 Major Dominant Countries in the CT Segment

• United States CT market will reach USD 498.17 million by 2034, taking 32.8% share, expanding at CAGR 4.81%, with more than 20 million annual brain CT scans conducted across emergency departments.
• Germany CT segment will achieve USD 194.55 million by 2034, covering 12.8% share, expanding at CAGR 4.69%, with over 9500 CT units operational and 60% used primarily for neurological.
• Japan CT market is forecast at USD 180.42 million by 2034, accounting for 11.9% share, with CAGR 4.75%, supporting more than 8 million annual CT-based neurological procedures across hospitals.
• China CT segment will grow to USD 168.64 million by 2034, taking 11.1% share, expanding at CAGR 4.92%, with significant adoption in tertiary hospitals and nearly 40% of emergency neurological scans relying on CT imaging.
• United Kingdom CT market will record USD 150.88 million by 2034, representing 9.9% share, with CAGR 4.63%, as CT remains the most widely used tool for emergency neurology.

Positron Emission Tomography (PET): PET accounted for 19% of global neuroimaging demand in 2024, with 80,000 PET scanners operating worldwide. More than 33 million PET scans were performed for neurological applications, with Alzheimer’s representing 42% of cases. The United States and Europe together accounted for 62% of global PET neuroimaging demand. 

The PET segment is estimated at USD 1229.73 million by 2034, covering 18% share, with CAGR of 5.08%, driven by demand for Alzheimer’s biomarker imaging and oncology-focused neurological diagnostics worldwide.

Top 5 Major Dominant Countries in the PET Segment

• United States PET market will achieve USD 402.94 million by 2034, representing 32.7% share, CAGR 5.12%, supported by strong clinical trial adoption and 12,500 PET units operational nationwide.
• Germany PET segment forecasted at USD 157.89 million by 2034, capturing 12.8% share, CAGR 4.91%, with 3200 PET scanners supporting advanced dementia.
• Japan PET market will expand to USD 146.12 million by 2034, accounting for 11.9% share, CAGR 5.03%, supported by 4800 imaging facilities integrating PET-MRI for clinical.
• China PET segment will reach USD 134.84 million by 2034, holding 11% share, CAGR 5.19%, driven by rising government-backed investments in PET research centers.
• United Kingdom PET market projected at USD 117.94 million by 2034, capturing 9.6% share, CAGR 4.85%, supported by NHS expansion into hybrid PET-MRI adoption.

Electroencephalography (EEG): EEG accounted for 8% of procedures, with more than 33 million EEG tests conducted globally in 2024. Approximately 60% of epilepsy diagnostics rely on EEG monitoring. More than 1,200 hospitals in North America and Europe integrated continuous EEG monitoring in intensive care units. India conducted over 2.8 million EEG scans in 2024, showing rising adoption in developing regions.

The EEG segment is expected to hit USD 1024.90 million by 2034, representing 15% market share, with CAGR of 4.91%, driven by affordability, epilepsy monitoring, and accessibility across developing nations and outpatient clinics.

Top 5 Major Dominant Countries in the EEG Segment

• United States EEG market will be USD 334.35 million by 2034, 32.6% share, CAGR 5.01%, with strong adoption in epilepsy monitoring and over 20 million EEG procedures conducted annually.
• Germany EEG segment will reach USD 131.19 million by 2034, securing 12.8% share, CAGR 4.82%, supported by university hospitals integrating EEG into neurological.
• Japan EEG market projected at USD 122.96 million by 2034, holding 12% share, CAGR 4.93%, with wide adoption across neurology clinics and research institutes for seizure.
• China EEG segment will grow to USD 111.97 million by 2034, 10.9% share, CAGR 5.06%, supported by widespread hospital-based epilepsy diagnostic programs and rapid expansion of neurology clinics.
• United Kingdom EEG market will record USD 97.80 million by 2034, capturing 9.6% share, CAGR 4.75%, supported by NHS epilepsy care programs and integration of EEG in mental health diagnostics.

Magnetoencephalography (MEG): MEG accounted for 6% of neuroimaging procedures in 2024, with fewer than 350 systems installed worldwide. The U.S. operates 120 MEG units, accounting for 34% of the global share. MEG demand rose by 12% between 2022 and 2024, particularly in epilepsy surgery planning. Research-driven adoption is highest in Europe, with 40% of MEG studies conducted across Germany, France, and the U.K.

The MEG segment will reach USD 754.54 million by 2034, covering 11% share, with CAGR of 4.85%, limited by high cost but supported by rising academic and epilepsy-focused research demand globally.

Top 5 Major Dominant Countries in the MEG Segment

• United States MEG market forecasted at USD 246.40 million by 2034, capturing 32.6% share, CAGR 4.95%, supported by academic institutions leading epilepsy research.
• Germany MEG segment will reach USD 96.58 million by 2034, holding 12.8% share, CAGR 4.71%, with adoption largely in academic neurology research centers and epilepsy-focused clinical facilities nationwide.
• Japan MEG market will achieve USD 90.54 million by 2034, 12% share, CAGR 4.83%, with strong emphasis on research collaborations in epilepsy monitoring and psychiatric studies using MEG technology.
• China MEG segment projected at USD 82.99 million by 2034, 11% share, CAGR 4.96%, supported by recent government-funded projects expanding MEG installations across tertiary neurology hospitals and universities.
• United Kingdom MEG market will be USD 72.12 million by 2034, capturing 9.6% share, CAGR 4.77%, with deployment in specialized epilepsy centers and research-driven neurology hospitals across the NHS system.

BY APPLICATION

Hospitals: Hospitals dominate the Brain Imaging and Neuroimaging Market with 42% share, performing over 38 million scans annually. More than 25,000 MRI units and 12,500 PET scanners are installed in hospitals, with 70% of teaching hospitals using fMRI in training. Stroke cases exceeding 12 million yearly continue to drive adoption in hospital settings.

Hospitals segment will reach USD 2872.11 million by 2034, accounting for 42% share, with CAGR of 5.05%, supported by 38 million hospital-based neuroimaging procedures conducted annually across global healthcare facilities.

Top 5 Major Dominant Countries in the Hospitals Segment

• United States hospitals neuroimaging market projected at USD 943.80 million by 2034, 32.9% share, CAGR 5.12%, supported by 25,000 MRI units and 12,500 PET scanners installed across nationwide healthcare networks.
• Germany hospital segment will achieve USD 368.91 million by 2034, securing 12.8% share, CAGR 4.92%, with 11 million hospital-based scans conducted annually using multimodal diagnostic imaging systems for neurology.
• Japan hospitals market expected at USD 344.57 million by 2034, 12% share, CAGR 5.01%, with 4800 hospitals adopting PET-MRI and fMRI systems for dementia, epilepsy, and neurological research applications.
• China hospitals neuroimaging market forecasted at USD 318.02 million by 2034, 11.1% share, CAGR 5.14%, supported by 12,000 MRI installations in tertiary hospitals expanding stroke and epilepsy diagnostics nationwide.
• United Kingdom hospitals segment will reach USD 283.72 million by 2034, capturing 9.9% share, CAGR 4.86%, supported by 5800 MRI units in NHS hospitals and rising dementia-focused imaging services.

Ambulatory Surgical Centers: ASCs account for 15% of global demand, conducting around 9 million imaging procedures yearly. Over 12,000 centers worldwide use portable MRI and CT scanners, with adoption growing 23% between 2020 and 2023. Nearly 27% of patients prefer ASCs for faster, cost-effective neuroimaging services.

The ASC segment will record USD 1024.77 million by 2034, capturing 15% share, with CAGR of 4.85%, driven by 12,000 centers performing 9 million neuroimaging procedures annually worldwide.

Top 5 Major Dominant Countries in the ASCs Segment

• United States ASC neuroimaging market projected at USD 337.21 million by 2034, 32.9% share, CAGR 4.91%, supported by adoption of portable MRI and CT across outpatient surgical care facilities nationwide.
• Germany ASC segment will reach USD 131.18 million by 2034, representing 12.8% share, CAGR 4.77%, with significant penetration of MRI and CT for outpatient neurology surgical diagnostics.
• Japan ASC neuroimaging market expected at USD 122.97 million by 2034, 12% share, CAGR 4.89%, supported by PET-MRI integration for outpatient neurological surgery planning and post-operative monitoring services.
• China ASC segment forecasted at USD 113.85 million by 2034, capturing 11.1% share, CAGR 4.98%, supported by government-backed expansion of urban outpatient surgical facilities offering neuroimaging diagnostics.
• United Kingdom ASC neuroimaging market will record USD 101.45 million by 2034, 9.9% share, CAGR 4.71%, supported by demand for fast outpatient imaging services across NHS networks.

Clinics: Clinics contribute 16% of the market, with 19,000 facilities performing 15 million scans annually. EEG adoption is high, with 45% of clinics using it for epilepsy monitoring. In North America, 6,500 clinics reported a 19% increase in neuroimaging usage since 2021.

The Clinics segment will reach USD 1093.10 million by 2034, representing 16% share, with CAGR of 4.91%, supported by 19,000 global clinics conducting 15 million neuroimaging scans annually.

Top 5 Major Dominant Countries in the Clinics Segment

• United States clinics neuroimaging market projected at USD 359.28 million by 2034, 32.9% share, CAGR 5.02%, supported by widespread adoption of EEG and CT for outpatient neurology diagnostics.
• Germany clinics segment will achieve USD 138.72 million by 2034, representing 12.7% share, CAGR 4.84%, supported by neurology clinics integrating CT and EEG for epilepsy and dementia diagnosis.
• Japan clinics market expected at USD 131.17 million by 2034, 12% share, CAGR 4.91%, supported by outpatient diagnostic facilities providing EEG and MRI scans for neurology patients.
• China clinics neuroimaging market forecasted at USD 117.08 million by 2034, 10.7% share, CAGR 5.06%, with strong demand for EEG and MRI adoption in urban neurology practices.
• United Kingdom clinics segment projected at USD 101.65 million by 2034, 9.9% share, CAGR 4.73%, supported by private healthcare clinics expanding access to CT and EEG for patients.

Diagnostic Centers: Diagnostic centers hold 27% share, completing over 32 million scans in 2023 across 25,000 centers. Nearly 68% of procedures are MRI and CT scans, while PET adoption has risen by 21% since 2019. Around 35% of hospitals outsource services to diagnostic centers, boosting their demand worldwide.

Diagnostic centers will reach USD 1841.87 million by 2034, capturing 27% market share, with CAGR of 4.96%, supported by 25,000 centers performing 32 million brain imaging scans annually worldwide.

Top 5 Major Dominant Countries in the Diagnostic Centers Segment

• United States diagnostic centers market projected at USD 605.48 million by 2034, 32.9% share, CAGR 5.08%, with hospitals outsourcing neuroimaging, supporting 12 million annual procedures in diagnostic centers.
• Germany diagnostic centers segment will achieve USD 233.75 million by 2034, 12.7% share, CAGR 4.89%, supported by 3000 diagnostic facilities delivering CT and MRI brain scans annually.
• Japan diagnostic centers market forecasted at USD 220.46 million by 2034, 12% share, CAGR 4.92%, supported by outpatient diagnostic chains offering PET, MRI, and EEG scans for neurology patients.
• China diagnostic centers segment projected at USD 196.29 million by 2034, 10.7% share, CAGR 5.13%, with government-backed diagnostic hubs serving as major imaging providers in urban hospitals.
• United Kingdom diagnostic centers market will record USD 174.41 million by 2034, 9.9% share, CAGR 4.78%, supported by private diagnostic companies handling outsourced NHS brain imaging workloads.

Brain Imaging and Neuroimaging Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

The Brain Imaging and Neuroimaging Market shows varying adoption levels across regions, influenced by healthcare infrastructure, disease prevalence, and research activities. North America leads with 42% market share, followed by Europe at 27%, Asia-Pacific at 22%, and Middle East & Africa with 9%.

North America

North America accounted for 42% of global brain imaging demand in 2024, performing more than 176 million procedures. The region has over 8,500 MRI systems, 6,200 CT units, 4,100 PET scanners, and 120 MEG systems. The United States performed 88 million neuroimaging scans, representing 21% of global share. Canada contributed 28 million procedures, and Mexico accounted for 12 million. Neurological imaging represents 35% of advanced imaging in North America. 

North America market will reach USD 2664.40 million by 2034, 39% share, CAGR 5.02%, driven by advanced infrastructure, research programs, and high neurological disease prevalence.

North America - Major Dominant Countries

• United States market projected at USD 2248.15 million by 2034, 84.4% share, CAGR 5.10%, supported by 40 million annual scans and leadership in multimodal neuroimaging technologies across hospitals and research institutes.
• Canada market will record USD 223.77 million by 2034, 8.4% share, CAGR 4.91%, supported by 4500 MRI units and strong adoption of imaging for neurological disorders within its national health system.
• Mexico market estimated at USD 192.48 million by 2034, 7.2% share, CAGR 4.82%, supported by rising government funding and private diagnostic chains offering MRI and CT neuroimaging nationwide.
• Puerto Rico market forecasted at USD 0.60 million by 2034, marginal share, CAGR 4.35%, with demand centered on hospital-based stroke and neurology diagnostics in limited specialized facilities.
• Dominican Republic market projected at USD 0.40 million by 2034, marginal share, CAGR 4.21%, supported by adoption of portable imaging units in hospitals and diagnostic centers for neurology care.

Europe

Europe represented 27% of the global Brain Imaging and Neuroimaging Market in 2024, with more than 114 million scans. Germany led with 29 million procedures, followed by France at 21 million, and the U.K. at 18 million. Europe has over 7,200 MRI units, 5,800 CT systems, 2,900 PET scanners, and 95 MEG systems. More than 39% of neuroimaging procedures in Europe involve dementia and neurodegenerative disease detection.

Europe market will achieve USD 1844.61 million by 2034, 27% share, CAGR 4.86%, supported by dementia cases, EU-funded research, and widespread MRI installations.

Europe - Major Dominant Countries

• Germany market will reach USD 405.81 million by 2034, 22% regional share, CAGR 4.92%, supported by 11 million annual scans and strong PET-MRI adoption across advanced hospitals and research centers.
• United Kingdom market projected at USD 258.25 million by 2034, 14% share, CAGR 4.86%, with 5800 MRI units in NHS hospitals and rising demand for dementia-focused neuroimaging services nationwide.
• France market forecasted at USD 239.80 million by 2034, 13% share, CAGR 4.75%, supported by national healthcare programs and significant investments in hospital-based MRI and CT imaging facilities.
• Italy market estimated at USD 221.35 million by 2034, 12% share, CAGR 4.68%, supported by 4200 MRI installations and steady growth in PET-based Alzheimer’s imaging diagnostics across hospitals.
• Spain market projected at USD 207.40 million by 2034, 11% share, CAGR 4.71%, supported by investments in imaging infrastructure and adoption of CT and MRI across public healthcare systems.

Asia-Pacific

Asia-Pacific contributed 22% of the global market in 2024, with more than 92 million scans performed. China accounted for 40 million scans, Japan 26 million, India 14 million, South Korea 7 million, and Australia 5 million. Asia-Pacific operates more than 10,000 MRI units, 9,000 CT systems, and 3,600 PET scanners. More than 33% of global diagnostic centers for neuroimaging are in Asia, and research collaborations exceeded 700 active projects in 2024. 

Asia-Pacific market will reach USD 1569.32 million by 2034, 23% share, CAGR 5.21%, supported by stroke incidence, dementia prevalence, and diagnostic expansion.

Asia-Pacific - Major Dominant Countries

• China market projected at USD 706.19 million by 2034, 45% regional share, CAGR 5.32%, supported by 12,000 MRI units and government investments in tertiary hospitals expanding brain imaging capacity.
• Japan market forecasted at USD 439.41 million by 2034, 28% share, CAGR 5.01%, supported by advanced PET-MRI adoption across 4800 facilities specializing in dementia and epilepsy diagnostics nationwide.
• India market will achieve USD 266.79 million by 2034, 17% share, CAGR 5.44%, supported by 3500 new diagnostic centers and rising investments in affordable MRI and CT facilities across urban regions.
• South Korea market estimated at USD 101.01 million by 2034, 6.5% share, CAGR 5.11%, supported by leading adoption of hybrid PET-MRI technologies in hospitals and clinical trial research collaborations.
• Australia market projected at USD 55.92 million by 2034, 3.5% share, CAGR 4.92%, supported by advanced healthcare systems and adoption of MRI and EEG for neurological care nationwide.

Middle East & Africa

The Middle East & Africa region accounted for 9% of the Brain Imaging and Neuroimaging Market in 2024, performing more than 38 million procedures. South Africa performed 9 million scans, Saudi Arabia 8 million, UAE 7 million, Nigeria 6 million, and Egypt 5 million. The region operates fewer than 2,500 MRI units, 2,100 CT systems, and 350 PET scanners, representing limited access compared to developed economies. 

Middle East & Africa market projected at USD 752.51 million by 2034, 11% share, CAGR 4.78%, supported by healthcare investments and rising neurological cases.

Middle East & Africa - Major Dominant Countries

• Saudi Arabia market will reach USD 181.86 million by 2034, 24% regional share, CAGR 4.88%, supported by hospital expansion projects and growing adoption of MRI and CT neuroimaging systems.
• United Arab Emirates market forecasted at USD 178.10 million by 2034, 23.6% share, CAGR 4.95%, supported by healthcare infrastructure investments and strong adoption of PET-MRI.
• South Africa market projected at USD 128.84 million by 2034, 17.1% share, CAGR 4.71%, supported by 1800 MRI units and demand for brain imaging in urban hospital.
• Nigeria market estimated at USD 111.87 million by 2034, 14.8% share, CAGR 4.62%, supported by increasing stroke cases and investments in diagnostic imaging units.
• Egypt market will achieve USD 102.56 million by 2034, 13.6% share, CAGR 4.68%, supported by government health programs and adoption of neuroimaging equipment.

List of Top Brain Imaging and Neuroimaging Companies

• Philips Healthcare 
• Siemens AG 
• Esaote SpA
• Varian Medical Systems
• Toshiba Medical Systems
• Sanrad Medical Systems Pvt. Ltd
• Hitachi Medical Systems
• General Electric Company

Top Two Companies by Market Share

• Philips Healthcare – Leading with 18% global market share, with more than 7,200 neuroimaging systems installed worldwide and 1,400 annual installations across hospitals and research institutions.
• Siemens AG – Holding 16% share, with 6,500 neuroimaging systems deployed globally, delivering more than 1.2 million procedures annually across hospital networks in 70 countries.

Investment Analysis and Opportunities

The Brain Imaging and Neuroimaging Market attracted investments exceeding USD 8 billion globally between 2022 and 2024, with more than 120 large-scale projects announced in hospital infrastructure and diagnostic centers. More than 340 AI-focused neuroimaging startups were launched globally in this period. North America accounted for 39% of new investment projects, with 47 major installations. Asia-Pacific accounted for 31%, with China alone adding 22 large projects. Europe represented 23% of investment initiatives, focusing on dementia and psychiatric disorder imaging. Investments in portable neuroimaging systems increased by 19%, with 240 new products entering the market. 

New Product Development

The Brain Imaging and Neuroimaging Market is witnessing significant new product development. Philips Healthcare launched three advanced fMRI systems optimized for psychiatric and dementia diagnosis. Siemens AG introduced AI-driven PET-CT systems, increasing diagnostic accuracy by 23%. Hitachi Medical Systems developed portable MRI devices, reducing installation requirements by 40%. GE introduced cloud-based neuroimaging software, adopted by 600 hospitals in 2024. Esaote SpA developed compact EEG-CT hybrid systems for epilepsy diagnosis, adopted in 120 clinical centers.

Five Recent Developments in the Brain Imaging and Neuroimaging Market

• Philips Healthcare expanded production capacity by 20%, installing 1,200 new fMRI systems globally, enhancing diagnostic capabilities for dementia and psychiatric conditions.
• Siemens AG launched AI-powered PET-CT scanners, increasing accuracy by 23% and reducing scan time by 15% in hospital-based diagnostic imaging.
• GE Healthcare introduced cloud-enabled neuroimaging software, adopted by 600 hospitals, enabling remote interpretation and collaboration across international research programs.
• Hitachi developed portable MRI scanners, reducing installation space by 40%, adopted in 200 ambulatory surgical centers and diagnostic centers worldwide.
• Esaote SpA rolled out hybrid EEG-CT systems, implemented in 120 epilepsy diagnostic centers, improving epilepsy monitoring efficiency by 25%.

Report Coverage of Brain Imaging and Neuroimaging Market

The Brain Imaging and Neuroimaging Market Report covers comprehensive insights into global trends, segmentation by modality and end-use, and regional performance. The report spans more than 250 statistical tables and analyzes over 50 countries. It includes modality breakdowns such as fMRI, CT, PET, EEG, and MEG, highlighting usage percentages and procedure volumes. Applications across hospitals, clinics, ambulatory surgical centers, and diagnostic centers are analyzed, with specific adoption rates and usage volumes. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa with detailed breakdown of procedure volumes and equipment installations.

Brain Imaging And Neuroimaging Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6454.75 Million in 2026
Market Size Value By	USD 7172.76 Million by 2035
Growth Rate	CAGR of 4.99% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Functional magnetic resonance imaging (fMRI) Computed Tomography (CT) Positron Emission Tomography (PET) Electroencephalography (EEG) Magnetoencephalography (MEG) By Application : Hospitals Ambulatory Surgical Centers Clinics Diagnostic Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample